The World Health Organization (WHO) has described a new strain of corona virus discovered in South Africa as a variant of concern.
This is the fifth type of concern, after which Alpha, Gamma, Beta and Delta were declared variant of concern.
A statement from the World Health Organization (WHO) said:
The announcement came after a meeting of experts from the World Health Organization on November 26, and for the first time in months, the WHO called a new strain of Corona a cause for concern.
The World Health Organization also said that the new species could spread faster than other species.
The statement added that preliminary evidence indicated that the new species could increase the risk of re-coding.
The statement added that there have been a number of mutations in this new species, some of which are cause for concern.
The WHO said the new species emerged much faster than previous types of waves, indicating that it has the potential to spread very fast.
Many governments around the world have tightened travel restrictions on countries in southern Africa since the discovery.
South Africa has called travel bans unfair.
Scientists are working to find out the details of this new type of corona to determine the extent to which it is contagious and does not resist covid vaccines.
BioNTech, a co-vaccine maker with Pfizer, said in a statement on November 26 that more data on the new coronavirus would be available in two weeks' time to determine if it How effective is the vaccine developed by the US and whether it needs to be changed?
The company said in a statement that it expects to gather more data from laboratory tests in the next two weeks to determine the extent to which B1.1.529 can withstand the vaccine and whether there is a need to change the vaccine.
The company added that the vaccine could be redesigned within 6 weeks if needed and the initial shipment would be available to countries within 100 days.
AstraZeneca also said in a statement that it was analyzing the effects of the new vaccine on vaccines and antibodies, and hoped that the combination of drugs would continue to be effective.
"We are reviewing B1.1.529 to learn about it and its effects on the vaccine," the statement said.
The company also announced that it was conducting data collection research in Botswana to test the new type of antibody in the real world.
